Search
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm.
Calcium glucoheptonate
go.drugbank.com/drugs/DB00326ApprovedInvestigationalCalcium is also needed for the heart, muscles, and nervous system to work properly. … Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium.
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalMilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment … yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934].
Cyclopentolate
go.drugbank.com/drugs/DB00979ApprovedA parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
N-Acetylglucosamine
go.drugbank.com/drugs/DB00141ApprovedInvestigationalNutraceuticalThe N-acetyl derivative of glucosamine.
Acute Myeloid Leukemia
go.drugbank.com/conditions/DBCOND0029883Drugs: Azacitidine · Cedazuridine · Cyclophosphamide · Cytarabine · Decitabine · Doxorubicin +9 moreSynonyms: Acute myeloid leukemia, no International Classification of Diseases for Oncology subtypeElapegademase
go.drugbank.com/drugs/DB14712ApprovedIt can be defined molecularly as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and with about 13 methoxy polyethylene glycol chains bound via carbonyl
Calcium glycerophosphate
go.drugbank.com/drugs/DB11264ApprovedBy FDA, calcium glycerophosphate is considered a generally recognized as safe (GRAS) food ingredient as a nutrient supplement (source of calcium or phosphorus), or in food products such as gelatins, puddings … It is also present in dental or oral hygiene products due to its cariostatic effects.
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Otelixizumab
go.drugbank.com/drugs/DB05496InvestigationalOtelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling.